The MASTERMIND-Pneumonia Study (also known as Pneumonia Direct Pilot Study) is designed to assess whether combining molecular diagnostics for bacteria and AMR markers with host-response profiling improves agreement and predictive value for the diagnosis of VAP versus an adjudicated clinical reference standard. The feasibility design is intended to inform future interventional studies that will investigate the clinical impact of combined pathogen- and host-directed testing approaches.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
The number of participants with positive results on the Respiratory Pathogen ID/AMR Enrichment Panel (Illumina)
Timeframe: Through study completion, or up to 18 months, whichever comes first
The number of participants with positive results on the Metagenomic Next Generation Sequencing (Illumina)
Timeframe: Through study completion, or up to 18 months, whichever comes first
The number of participants with positive results on the T2 Bacteria Panel (T2 Biosystems)
Timeframe: Through study completion, or up to 18 months, whichever comes first
The number of participants with positive results on the T2 Resistance Panel (T2 Biosystems)
Timeframe: Through study completion, or up to 18 months, whichever comes first
The number of participants with positive results on the Procalcitonin (Abbott)
Timeframe: Through study completion, or up to 18 months, whichever comes first
The number of participants with positive results on the TriVerity host (Inflammatix)
Timeframe: Through study completion, or up to 18 months, whichever comes first
The number of participants with positive results on the Host gene expression
Timeframe: Through study completion, or up to 18 months, whichever comes first
The number of participants with positive results on the FilmArray Pneumonia Panel (BioFire)
Timeframe: Through study completion, or up to 18 months, whichever comes first
Number of participants with a clinical diagnosis of VAP at the time of clinical change
Timeframe: day 15